Modulation of apoptotic pathways by curcumin and resveratrol conveysneuroprotection against rotenone-induced toxicity in SH-SY5Y cells.
Makaleler > Tam Makale · 2024
Yazarlar: Betül Genç, Meltem Yılmaz Coşar, Mümin Alper Erdoğan, Özlem YILMAZ
The Annals of Clinical and Analytical Medicine, ESCI İndekslerine Giren Dergi, Uluslararası, Emerging Sources Citation Index (ESCI), 2024, cilt 1, ss 570-574
DOI: 10.4328/ACAM.22183
Özet
<p>Apoptotic modulation by curcumin and resveratrol in SH-SY5Y cells Abstract Aim: This study investigates the neuroprotective properties of the polyphenolic compounds resveratrol and curcumin against rotenone-induced toxicity in SH-SY5Y neuronal cells. Material and Methods: The cytotoxic threshold (LD50) of rotenone was established through a dose-response assessment in SH-SY5Y cells. Cells were pre-incubated with varying concentrations of resveratrol (1-100 µM) and curcumin (10-1000 nM), followed by a 24-hour rotenone challenge (200 nM). Cell survival was gauged using the MTS assay, while caspase-3 levels, as a marker of apoptosis, were quantified via ELISA. The capability of cells to form colonies post-treatment was determined through a clonogenic survival assay. Moreover, the Western blot analysis revealed that pre-treatment with resveratrol and curcumin significantly modulated the protein expression levels of Bax and Bcl-2. Results: Pretreatment with resveratrol and curcumin significantly enhanced cell viability and clonogenic survival in the presence of rotenone, with notable decreases in caspase-3 levels, implying reduced apoptosis (p < 0.05). These compounds also modulated the expression of Bax and Bcl-2, contributing to their protective effects. Discussion: Resveratrol and curcumin exhibit promising neuroprotective effects by improving cell survival and modulating apoptotic markers in SH-SY5Y cells subjected to rotenone-induced toxicity. These findings support the potential therapeutic role of these polyphenols in neurodegenerative disease management, pending further validation through comprehensive pre-clinical and clinical studies.</p>